| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9763885 | ALTHERA PHARMS | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
May, 2033
(9 years from now) | |
| US10376470 | ALTHERA PHARMS | Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases |
May, 2033
(9 years from now) | |
Roszet is owned by Althera Pharms.
Roszet contains Ezetimibe; Rosuvastatin Calcium.
Roszet has a total of 2 drug patents out of which 0 drug patents have expired.
Roszet was authorised for market use on 23 March, 2021.
Roszet is available in tablet;oral dosage forms.
Roszet can be used as treatment of hyperlipidemia.
The generics of Roszet are possible to be released after 01 May, 2033.
Drugs and Companies using EZETIMIBE; ROSUVASTATIN CALCIUM ingredient
Market Authorisation Date: 23 March, 2021
Treatment: Treatment of hyperlipidemia
Dosage: TABLET;ORAL
More Information on Dosage
ROSZET family patents
